Your browser doesn't support javascript.
Persistence of robust humoral immune response in COVID-19 convalescent individuals over 12 months after infection
Kei Miyakawa; Sousuke Kubo; Sundararaj Stanleyraj Jeremiah; Hirofumi Go; Yutaro Yamaoka; Norihisa Ohtake; Hideaki Kato; Satoshi Ikeda; Takahiro Mihara; Ikuro Matsuba; Naoko Sanno; Masaaki Miyakawa; Masaharu Shinkai; Tomoyuki Miyazaki; Takashi Ogura; Shuichi Ito; Takeshi Kaneko; Kouji Yamamoto; Atsushi Goto; Akihide Ryo.
  • Kei Miyakawa; Yokohama City University Graduate School of Medicine
  • Sousuke Kubo; Yokohama City University Graduate School of Medicine
  • Sundararaj Stanleyraj Jeremiah; Yokohama City University Graduate School of Medicine
  • Hirofumi Go; Yokohama City University Graduate School of Medicine
  • Yutaro Yamaoka; Kanto Chemical Co, Inc.
  • Norihisa Ohtake; Tosoh Corporation
  • Hideaki Kato; Yokohama City University Hospital
  • Satoshi Ikeda; Kanagawa Cardiovascular and Respiratory Center
  • Takahiro Mihara; Yokohama City University Graduate School of Data Science
  • Ikuro Matsuba; Matsuba Medical Clinic
  • Naoko Sanno; Shinagawa Strings Clinic
  • Masaaki Miyakawa; Miyakawa Internal Medicine and Pediatrics Clinic
  • Masaharu Shinkai; Tokyo-Shinagawa Hospital
  • Tomoyuki Miyazaki; Yokohama City University Graduate School of Medicine
  • Takashi Ogura; Kanagawa Cardiovascular and Respiratory Center
  • Shuichi Ito; Yokohama City University Graduate School of Medicine
  • Takeshi Kaneko; Yokohama City University Graduate School of Medicine
  • Kouji Yamamoto; Yokohama City University Graduate School of Medicine
  • Atsushi Goto; Yokohama City University Graduate School of Data Science
  • Akihide Ryo; Yokohama City University Graduate School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-21264013
ABSTRACT
SARS-CoV-2 infection elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). Here we report the persistence of nAb responses over 12 months after infection despite its decreasing trend noticed from 6 months. The study included sera from 358 individuals who had been infected with SARS-CoV-2 between January and May 2020. Samples were collected at 6 and 12 months after onset. The titers of IgG to the viral nucleocapsid protein (NP) and receptor-binding domain of the spike protein (RBD) were measured by CLEIA. The nAb titer was determined using lentivirus-based pseudovirus or authentic virus. Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. While the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases ([~]30%) was undermined, implying the susceptibility of reinfection to the variants of concerns (VOCs). COVID-19 convalescent individuals have robust humoral immunity even at 12 months after infection albeit that the medical history and background of patients could affect the function and dynamics of antibody response to the VOCs.
Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2021 Document Type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2021 Document Type: Preprint